Antagonists of ET-1 have been evaluated in clinical trials for use in idiopathic pulmonary fibrosis (IPF) with limited success, but there is clearly a biological rationale for ET-1 in pulmonary fibrosis which still supports antagonism and/or decreased levels of protein as providing a potential therapeutic advantage [29,30]. The gene discussed is EDN1; the disease is pulmonary fibrosis.